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Abstract
Receptor-targeted lentiviral vectors (LVs) can be an effective tool for selective transfer of
genes into distinct cell types of choice. Moreover, they can be used to determine the molec-
ular properties that cell surface proteins must fulfill to act as receptors for viral glycoproteins.
Here we show that LVs pseudotyped with receptor-targeted Nipah virus (NiV) glycoproteins
effectively enter into cells when they use cell surface proteins as receptors that bring them
closely enough to the cell membrane (less than 100 Å distance). Then, they were flexible in
receptor usage as demonstrated by successful targeting of EpCAM, CD20, and CD8, and
as selective as LVs pseudotyped with receptor-targeted measles virus (MV) glycoproteins,
the current standard for cell-type specific gene delivery. Remarkably, NiV-LVs could be pro-
duced at up to two orders of magnitude higher titers compared to their MV-based counter-
parts and were at least 10,000-fold less effectively neutralized than MV glycoprotein
pseudotyped LVs by pooled human intravenous immunoglobulin. An important finding for
NiV-LVs targeted to Her2/neu was an about 100-fold higher gene transfer activity when par-
ticles were targeted to membrane-proximal regions as compared to particles binding to a
more membrane-distal epitope. Likewise, the low gene transfer activity mediated by NiV-LV
particles bound to the membrane distal domains of CD117 or the glutamate receptor subunit
4 (GluA4) was substantially enhanced by reducing receptor size to below 100 Å. Overall,
the data suggest that the NiV glycoproteins are optimally suited for cell-type specific gene
delivery with LVs and, in addition, for the first time define which parts of a cell surface protein
should be targeted to achieve optimal gene transfer rates with receptor-targeted LVs.
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Author Summary
Pseudotyping of lentiviral vectors (LVs) with glycoproteins from other enveloped viruses
has not only often been revealing in mechanistic studies of particle assembly and entry,
but is also of practical importance for gene delivery. LVs pseudotyped with engineered gly-
coproteins allowing free choice of receptor usage are expected to overcome current limita-
tions in cell-type selectivity of gene transfer. Here we describe for the first time receptor-
targeted Nipah virus glycoproteins as important step towards this goal. LV particles carry-
ing the engineered Nipah virus glycoproteins were substantially more efficient in gene
delivery than their state-of-the-art measles virus-based counterparts, now making the pro-
duction of receptor-targeted LVs for clinical applications possible. Moreover, the data
define for the first time the molecular requirements for membrane fusion with respect to
the position of the receptor binding site relative to the cell membrane, a finding with
implications for the molecular evolution of paramyxoviruses using proteinaceous recep-
tors for cell entry.
Introduction
Cell entry as first step in the viral replication cycle is initiated by the attachment of virus parti-
cles to distinct cell surface proteins. While many viral receptors have been identified, there is
only limited knowledge available about the molecular requirements that cell surface proteins
have to fulfill to act as entry receptors and why they have been chosen during viral evolution
[1]. Paramyxoviruses encode two envelope proteins required for cell entry, the receptor attach-
ment protein and the fusion protein (F) which mediates fusion of the viral and cellular mem-
branes upon receptor contact. Three types of attachment proteins can be distinguished, the
hemagglutinin-neuraminidase (HN), the hemagglutinin (H) and the glycoprotein (G), which
in contrast to the others has no hemagglutinating function. All attachment proteins are type II
membrane proteins with a membrane proximal stalk domain and a propeller-like head domain
[2]. While HN proteins use sialic acid as receptor, morbillivirus H and henipavirus G recognize
proteinaceous receptors. Due to this and its separated attachment and fusion functions, the
measles virus (MV) H protein has been the first viral attachment protein that was successfully
engineered to use a cell surface protein of choice for entry instead of its natural receptor [3].
While this approach suggested a high flexibility in receptor usage for MV, it was also of
applied relevance for the engineering of tumor–specific oncolytic viruses [4] and when com-
bined with pseudotyping for the generation of cell-type specific lentiviral vectors (LVs). With
LVs as a major tool, gene therapy has developed to one of the most important technologies in
modern medicine for the treatment of monogenetic diseases as well as various cancer types [5–
7]. LVs mediate stable long-term expression and integration of transgenes into the genome of
transduced cells. The commonly used LVs for therapeutic applications are pseudotyped with
either the glycoprotein G of the vesicular stomatitis virus (VSV) or the envelope (Env) proteins
of γ-retroviruses such as murine leukemia virus (MLV) or, more recently, the baboon retrovi-
rus [8]. Since the use of all these glycoproteins result in LVs with a broad cellular tropism
allowing gene transfer into a variety of cell types, further modifications in vector design have
been established to restrict gene transfer into the cell type relevant for a given application.
The concept of engineering vector particle entry relies on targeting the particles to a cell sur-
face protein of choice which is then used as entry receptor [9,10]. By picking surface proteins
that are selectively expressed in a particular cell type, gene transfer can be restricted to this cell
type. Natural receptor usage is destroyed through mutating specific residues in the attachment
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protein and the desired receptor usage is achieved through displaying a polypeptide (targeting
domain) exhibiting high affinity for the targeted receptor. So far, the envelope glycoproteins
from three different viruses have been successfully engineered to generate such receptor-tar-
geted LVs. While all available receptor-targeted LVs work in principle, they also have certain
disadvantages making their broad application and translation into the clinic difficult.
LVs pseudotyped with receptor-targeted Sindbis virus glycoproteins have been developed
for a large variety of cell types but are limited by the non-covalent linkage of the targeting
domain, the requirement for low pH membrane fusion triggering provided by efficient endocy-
tosis of the targeted receptor as well as insufficient selectivity, which often has been compen-
sated by the use of cell-type specific promoters [11–13]. A similar large number of cell surface
proteins has been targeted by engineered MV glycoproteins, resulting in LVs exhibiting high
selectivity for their target cells even when combined with the strong and ubiquitously active
spleen focus forming virus (SFFV) promotor [10,14]. MV-based receptor-targeted LVs, how-
ever, can only be produced at moderate titers and are susceptible towards neutralizing antibod-
ies induced by MV vaccination, thus preventing multiple dosing in patients. While the latter
problem may be circumvented by engineered Tupaia paramyxovirus (TPMV) glycoproteins,
this system turned out to be too inefficient in vector production [15].
To address the disadvantages of the MV- and TPMV-based systems, while keeping their
high selectivity, we generated here for the first time receptor-targeted glycoproteins derived
from a henipavirus. Nipah virus (NiV) is naturally harbored by fruit bats and can cause fatal ill-
ness in humans with respiratory and encephalitic symptoms [16]. As no vaccination programs
against NiV exist, neutralizing antibodies in the human population are vanishingly small. Pre-
vious studies showed that LVs can be pseudotyped with the NiV glycoproteins resulting in vec-
tor stocks with high titers, although different cytoplasmic tail truncations were found to be
optimal [17–19]. These results suggest that the NiV glycoproteins may be more suited for the
generation of receptor-targeted LVs than those of MV or TPMV. Here we show, that LVs pseu-
dotyped with the engineered NiV glycoproteins delivered genes to their target cells as selec-
tively as MV-based receptor-targeted LVs but could be produced at substantially higher titers.
Notably, receptor-targeted NiV-LVs turned out to be highly sensitive towards the position of
their binding site on the targeted receptor, with membrane-proximal positions being preferred
over membrane-distal ones.
Results
Setting up the system
Previous studies showed that LVs can be pseudotyped with the NiV glycoproteins resulting in
vector stocks with high titers [17–19]. While these studies showed that successful pseudotyping
is achieved by cytoplasmic tail truncation of the fusion protein F, only Witting et al. (2013)
[19] found that the glycoprotein G had to be truncated as well, while others came to different
conclusions [17–19]. In order to generate targeted NiV-LVs, we therefore first tested the previ-
ously described cytoplasmic tail variants of NiV G and F (Fig 1A). As target receptor we chose
the human epithelial cell adhesion molecule (EpCAM), a putative marker of early tumor cells
[20], and fused the EpCAM-specific DARPin Ac1 [21] to the ectodomain of the G protein cyto-
plasmic tail variants. All nine combinations of the resulting GEpCAM and F (Fig 1A) variants
were assessed for their ability to mediate transfer of the gfp gene into CHO-EpCAM cells. CHO
cells lack the natural NiV receptors ephrin-B2 and ephrin-B3 and are not susceptible for NiV.
Gene transfer into CHO-EpCAM cells must therefore have been mediated by entry via human
EpCAM. All NiV-LVs tested showed transduction of CHO-EpCAM cells (Fig 1B). The highest
titers were obtained when the cytoplasmic tail of the F protein was truncated by 22 residues
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and that of the GEpCAM protein by 33 or 34 amino acids, with a slight but not significant advan-
tage for GcΔ34, resulting in unconcentrated titers of 4-5x105 t.u./ml. The differences in titers
were not due to differences in the cell surface expression levels of the GEpCAM variants, since
HEK-293T cells transfected with plasmids encoding the three different constructs showed sim-
ilar high surface expression levels (Fig 1C; S1 Fig).
Next, incorporation of the GEpCAM variants into LV particles was investigated. Particles
pseudotyped with all nine combinations of GEpCAM, GcΔ33EpCAM or GcΔ34EpCAM with F,
FcΔ22 or FcΔ25 were produced, normalized by particle numbers and analyzed via Western
blot analysis. As controls, we also produced LV stocks pseudotyped with untruncated but His-
tagged G/F (GHis-LV) or with GcΔ34His/FcΔ22 (NiVwt-LV). All G and F variants were incor-
porated into vector particles (Fig 1D). When correlated to the intensities of the p24 signals,
GcΔ33EpCAM and GcΔ34EpCAM showed substantially higher incorporation levels than GEpCAM
and GHis carrying full-length C-tails (S2 Fig), which corresponds well to the higher vector titers
observed for these constructs. The combination GcΔ34EpCAM and FcΔ22 was used for further
vector productions.
As the ratio of G to F in the viral envelope can influence virus-cell fusion and thus LV entry,
we aimed to determine the optimal ratio of plasmids. Ratios of plasmids ranging from a tenfold
excess of F- over G-encoding plasmid to a tenfold excess of G over F were tested. Overall,
higher amounts of the GcΔ34EpCAM encoding plasmid reduced LV titers (Fig 1E). The optimal
ratio was determined to be a five-fold excess of the FcΔ22 encoding plasmid, which was used
for all further LV productions.
Blinding the NiV glycoprotein G for its natural receptors
As the GcΔ34EpCAM protein described above still recognizes the natural NiV receptors ephrin-
B2 and B3, we aimed at completely restricting gene transfer to hEpCAM+ cells by destroying
the natural receptor usage of NiV-G in the next step. For this purpose, six point mutations, pre-
viously described to influence the natural receptor recognition and cell entry of Nipah or Hen-
dra virus [22–24], were introduced into GcΔ34EpCAM individually or in combinations. All
mutated residues localize in the contact area of NiV-G and ephrin-B2 (Fig 2A) [25,26]. For all
GcΔ34EpCAM proteins with a single point mutation the position and type of mutation is indi-
cated in their respective designation. The three variants carrying combined mutations were
termed as follows: GcΔ34EpCAMmut2.1 includes mutations E501A+W504A, GcΔ34EpCAM-
mut2.2 mutations Q530A+E533A, and GcΔ34EpCAMmut4 mutations E501A, W504A, Q530A
and E533A. U87-MG cells, a glioblastoma cell line known to be highly susceptible for NiV
infections, was used to determine ephrin-B2/B3 receptor usage by the LVs pseudotyped with
Fig 1. Establishing the pseudotyping of LV particles with DARPin-displaying NiV glycoproteins. (A) Schematic drawing of modified NiV envelope
proteins. The glycoprotein G variant consisting of differently truncated cytoplasmic tails (CT), transmembrane domain (TM), ectodomain (ED), the fused
EpCAM-specific DARPin Ac1 and a His tag is shown in the top row. Below, the schematic drawing of the fusion protein (F) cytoplasmic tail variants is
shown. (B) Unconcentrated screening titers (t.u./ml) of all nine combinations of G and F protein variants titrated on CHO-EpCAM cells (n = 3;
mean ± standard deviations (SD) are shown; ****, P<0.0001; ns, not significant by one-way ANOVA with Tukey's multiple comparisons test). (C) Surface
expression of EpCAM-targeted G variants on HEK-293T cells transiently transfected with the corresponding expression plasmids (empty curves) compared
to mock transfected cells (filled curves) as determined by flow cytometry. Cells were stained with PE-coupled anti-His antibody. One representative out of
three experiments is shown. For quantitative data see S1 Fig. (D) Western blot analysis of LV particles for incorporation of GEpCAM, GcΔ33EpCAM, and
GcΔ34EpCAM and the three different F variants (full length F, FcΔ22 and FcΔ25). For generation of LVs used for Western blot analysis, in contrast to other
vector productions, F protein with C-terminally fused AU1 tag was used in order to allow detection via an anti-AU1 antibody. Incorporation of the G variants
was detected via an anti-His antibody. 2.5x1010 particles per sample were applied. NiV-GHis/F (GHis-LV) and GcΔ34His/FcΔ22 (NiVwt-LV) pseudotyped LVs
as well as concentrated supernatant of mock transfected cells (mock) and concentrated supernatant of cells transfected with the gag/pol encoding plasmid
pCMVΔR8.9 only (bald-LV) served as controls. M indicates the marker lane. For quantitative data see S2 Fig. (E) In order to optimize titers, the ratio of the
amounts of the plasmids encoding the GcΔ34EpCAM and the FcΔ22 protein was varied for vector production in HEK-293T cells as indicated. The produced
vector stocks were titrated on CHO-EpCAM cells, and their relative titers, normalized to that obtained after transfection of the 1:3 ratio, is shown.
doi:10.1371/journal.ppat.1005641.g001
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the mutated GcΔ34EpCAM proteins. To control that the mutations in GcΔ34EpCAM did not affect
the fusion-helper function of G but selectively inhibited recognition of ephrin-B2/B3, LVs were
assessed for their ability to transduce ephrin-B2/B3 negative CHO-EpCAM cells. As expected,
LVs pseudotyped with GcΔ34 and FcΔ22 transduced U87-MG cells but not CHO-EpCAM
cells, while GcΔ34EpCAM carrying LVs transduced both cell types (Fig 2B). Of the six single
mutations three showed a significant negative impact on gene delivery into U87-MG cells (Fig
2B, black bars), with the mutation at position 533 (E533A) being most effective. Combining
Q530A with E533A showed a slight advantage over the combination of E501A with W504A or
the single mutations. None of the mutations significantly influenced the transduction of
CHO-EpCAM cells (Fig 2B, white bars).
To clearly demonstrate that the mutations in GcΔ34EpCAM interfere with binding to the nat-
ural NiV receptors, the ability to bind soluble recombinant ephrin-B2 and ephrin-B3 was ana-
lyzed by a flow cytometry-based binding assay. Interestingly, even though mutant E533A and
Q530A+E533A (mut2.2) showed only very low levels of transduction, binding of ephrin-B2,
but not of ephrin-B3, could still be detected (Fig 2C and 2D). Only binding of ephrin-B3 was
clearly impaired indicating that LV entry into U87-MG is mediated by binding of NiV-G to
ephrin-B3 (Fig 2D). Importantly, when combining the four mutations in construct GcΔ34Ep-
CAMmut4, binding of recombinant ephrin-B2 dropped to background levels as well (Fig 2C).
Therefore, this mutant was used for all further experiments to ensure entry and binding to be
ephrin-B2/B3 independent.
To further characterize the NiVmutEpCAM-LV particles, their size was determined by single
nanoparticle tracking (NanoSight). The average particle size peaked at 138 nm (± 4.4) (Fig 2E).
This is a slight increase over NiVwt-LV (GcΔ34/FcΔ22 pseudotyped), which showed a peak
size of 130 nm (± 3.2), probably due to fusion of the DARPin to the NiV-G protein. For com-
parison, VSV-LV, vector particles pseudotyped with the glycoprotein G of vesicular stomatitis
virus, had a diameter of 116 nm (± 3.2) (Fig 2E). Electron microscopy of concentrated NiVmu-
tEpCAM-LV stocks revealed numerous particles exhibiting the typical morphology of HIV-1
core particles. On their surface, a homogeneous high-density layer of spike proteins was readily
detectable (Fig 2F).
To assess the selectivity of gene transfer mediated by NiVmutEpCAM-LV, CHO-K1 cells
which are negative for both, EpCAM and ephrin-B2, CHO-ephrin-B2 and CHO-EpCAM cells
were transduced either individually or in mixed cultures, where EpCAM+ and EpCAM- cells
are cultivated in close contact. VSV-LV transduced all these cell lines equally efficient.
NiVwt-LV selectively transduced CHO-ephrin-B2 cells in single and mixed culture, while
Fig 2. Mutation of the NiV glycoprotein to ablate natural receptor recognition. (A) Surface representation of top-view of NiV-G. G is shown as dimer
by modeling its monomer crystal structure (Protein Data Bank (PDB) ID: 3D11) on the crystal structure of the Hendra virus G dimer (PDB ID: 2X9M) using
PyMOL. The binding site for ephrin-B2 is depicted in blue [26]. Residues mutated in G to screen for their potential to ablate natural receptor tropism are
shown in red. (B) Six different single mutations and the combinations E501A+W504A (GcΔ34EpCAMmut2.1), Q530A+E533A (GcΔ34EpCAMmut2.2), or
E501A+W504A+Q530A+E533A (GcΔ34EpCAMmut4) were introduced into GcΔ34EpCAM. Unconcentrated vector stocks generated with the mutated G
proteins were titrated on CHO-EpCAM (white bars; negative for natural NiV receptors) and U87-MG cells (black bars; positive for NiV receptors). NiV-LVs
pseudotyped with GcΔ34/FcΔ22 having the natural NiV tropism (GcΔ34) served as control. Arrows indicate titers <6x102 t.u./ml. Statistics refer to
unmutated GcΔ34EpCAM. Titers of EpCAM-targeted LVs on CHO-EpCAM cells were not statistically different. (n = 4; mean ± standard deviations (SD) are
shown; *, P<0.1 **, P<0.01 by one-way ANOVA with Dunnett's multiple comparisons test). (C-D) Binding of ephrin-B2 (C) and B3 (D) to NiV-G mutants is
shown. HEK-293T cells were transfected either mock or with plasmids encoding the indicated G protein variants and then incubated with 1 μg/ml
recombinant Fc-ephrin-B2 or -B3 prior to staining against the Fc-tag using FITC coupled anti-Fc antibody. The binding efficiencies of the different mutants
to the receptors are shown as MFI (mean fluorescence intensity) values (n = 3; mean ± standard deviations (SD) are shown). (E) Concentrated vector
stocks of GcΔ34EpCAMmut4/FcΔ22 pseudotyped LV vectors were generated and particle size was analyzed via single nanoparticle tracking analysis
(NTA). Particle size measurement of one representative out of three independent stocks is shown (black). As control, concentrated vectors stocks of
VSV-LV (blue) and NiVwt-LV (red) were analyzed. The mean size ± SD of the main peak out of three measurements of each particle type is indicated. (F)
Electron microscopy of concentrated LV particles pseudotyped with GcΔ34EpCAMmut4/FcΔ22 proteins. The white arrowhead points to the NiV
glycoproteins on the particle surface. Scale bar: 100 nm.
doi:10.1371/journal.ppat.1005641.g002
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NiVmutEpCAM-LV selectively transduced only CHO-EpCAM cells (Fig 3A). On receptor-nega-
tive cells at most 0.1% GFP-positive cells were detectable. This was also the case for CHO-
ephrin-B2 cells, demonstrating that natural receptor usage had been completely ablated by the
introduced point mutations (Fig 3A). The selective gene transfer mediated by NiVmutEpCAM-
LV was stable over a period of 30 days of cultivating the transduced cells (Fig 3B). GFP protein
transfer can therefore be ruled out and integration of the gfp reporter gene into the host cell
chromosomes assumed.
To verify cell entry via the targeted receptor, NiVwt-LV or NiVmutEpCAM-LV were incu-
bated with increasing amounts of the entire extracellular domain of human ephrin-B2, ephrin-
B3, human EpCAM or murine EpCAM as a control at 4°C for 1 h prior to transduction of tar-
get cells. For NiVwt-LV, a dose-dependent decrease in the transduction of CHO-ephrin-B2
cells with increasing concentrations of recombinant ephrin-B2 was documented, whereas
human or murine EpCAM did not influence transduction (Fig 4A). Ephrin-B3, which is
known to bind to the same site on the NiV G protein as ephrin-B2, also competed with gene
transfer via ephrin-B2 but at much higher concentrations. NiVmutEpCAM-LV, in contrast,
was only competed by human EpCAM but neither by murine EpCAM nor ephrin-B2 or -B3
(Fig 4B).
To examine if cell entry of the NiV-pseudotyped LVs was pH-independent, as described for
Nipah virus [27], acidification of endosomes was blocked with bafilomycin A1. VSV-LV medi-
ated gene transfer was strongly reduced by bafilomycin A1 which corresponds to its well estab-
lished pH-dependent cell entry [28] (Fig 4C). In contrast, the transduction by NiVwt-LV was
not affected. Surprisingly, gene transfer mediated by NiVmutEpCAM-LV was even enhanced
upon bafilomycin A1 treatment (Fig 4C). These data demonstrate that NiVmutEpCAM-LV
enters cells pH-independently.
Expanding the system to additional target receptors
Next, we asked if other surface proteins can be targeted by engineered NiV glycoproteins as
well. Human CD8, a marker for cytotoxic T cells, human CD20, a marker for B cells, and
Her2/neu, a marker for breast cancer, were targeted as described previously for MV glycopro-
tein pseudotyped LVs [29–31]. As targeting ligands, we used DARPin 9.29 for Her2/neu [30],
and single chain antibodies (scFv) specific for CD8 [29] or CD20 [31]. Each G variant was
expressed at the cell surface to the same level as that of the corresponding MV-HcΔ18mut vari-
ant, respectively (Fig 5A; S3 Fig). In addition, they were incorporated into the LV particles with
a tendency for higher incorporation levels of the DARPin- over the scFv-displaying G proteins
(Fig 5B; S4 Fig). Several batches of all four NiV-based and the corresponding MV-based recep-
tor-targeted vectors were generated and titrated on cell lines expressing the targeted receptor.
Interestingly, we observed 10-100-fold higher titers for NiVmutEpCAM-LV, NiVmutCD20-LV,
and NiVmutCD8-LV compared to their MV-based counterparts (Fig 5C and 5D). Notably,
NiVmutHer2-LV was an exception. Here, the titer was reduced 30-fold when compared to its
MV-based counterpart (Fig 5C and 5D). Importantly, concentrating the vector particles did
not impair transduction efficiency with recovery rates of 80.8 to 96.9% (Fig 5E). When super-
natant from packaging cells cultivated in ten T175 flasks was concentrated down to 0.6 ml,
titers of above 108 t.u./ml were obtained.
To identify potential reasons for the increased titers of receptor-targeted LVs based on the
NiV glycoproteins, particle numbers in all concentrated vector stocks were determined by sin-
gle nanoparticle tracking analysis. All NiV-based LV stocks contained between three- to five-
fold higher particle numbers than the corresponding MV-based LV stocks (S5 Fig). In 108 par-
ticles, all the NiV pseudotyped LV stocks contained more transducing units, than the
Receptor-Targeted Nipah Virus Glycoproteins
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corresponding MV-based LVs (Fig 5F). This holds true especially for the NiV-based CD8 and
CD20 targeted LVs which exhibited more than 10-fold higher values (Fig 5F). Thus, the higher
gene transfer activity observed for the NiV-based receptor-targeted LVs must be due to a mix-
ture of two aspects: On the one hand, more particles are released during production and on the
other hand, the particles are more active.
NiV-based lentiviral vectors are resistant towards intravenous
immunoglobulins
Due to the vaccination against measles virus, MV-based LVs become neutralized by human
serum to at least some extent even though receptor-targeted MV-LVs exhibit some level of pro-
tection [32]. Since there is no vaccination against NiV and the outbreaks were limited to a few
cases in Malaysia, Bangladesh and India [33], there should be no neutralizing antibodies pres-
ent in humans. To cover the widest range of human serum donors, intravenous immunoglobu-
lin (IVIG; Intratect), which contains serum from many thousand donors, was incubated with
NiVwt-LV, NiVmutEpCAM-LV, MVEpCAM-LV and VSV-LV at increasing concentrations prior
to the transduction of target cells. MVEpCAM-LV showed a dose-dependent decrease in trans-
duction rates and was completely neutralized at 10 μg/ml of IVIG. In contrast, VSV-LV,
NiVwt-LV and also NiVmutEpCAM-LV were resistant against IVIG at all concentrations used
and must thus be at least 10,000-fold less sensitive against human immunoglobulin than the
corresponding MV-based vector (Fig 6). These results suggest that receptor-targeted vectors
based on NiV glycoproteins will not be neutralized when injected into humans.
NiVmutCD8-LV selectively transduces CD8+ T cells in human PBMC
To prove that the established system does not only show selective transduction in cell lines but
does also transfer genes into primary cells, human peripheral blood mononuclear cells
(PBMC) were chosen as targets. Freshly isolated PBMC were activated for three days and trans-
duced with NiVmutCD8-LV. As controls, cells were transduced with VSV-LV or NiVwt-LV.
GFP expression was followed over a period of 5, 10 and 17 days. VSV-LV transduced both cell
fractions, CD8+ and CD8- (Fig 7A, top right diagram). NiVwt-LV was unable to transduce any
cell type present in human PBMC (Fig 7A). NiVmutCD8-LV, in contrast, selectively transduced
the CD8+ cells at high efficiency. The gene transfer mediated by NiVmutCD8-LV into CD8+
cells was stable for at least 17 days (Fig 7B). Notably, PBMC transduced by VSV-LV showed a
significant decrease in GFP+ cells over this period. This was most likely due to cells that had
not integrated the GFP gene but taken up GFP as protein. Thus, NiVmutCD8-LV cannot only
transduce selectively CD8+ populations in human PBMC but also ensures stable gene expres-
sion over time.
Characterization of NiVmutHer2–LV
To investigate the underlying mechanism resulting in the reduced titers of Her2/neu-targeted
NiV-based LV, surface expression of the GcΔ34Her2mut4 protein on HEK-293T producer cells
was assessed first, as this is a critical step for incorporation into budding vector particles.
Fig 3. Selectivity of NiVmutEpCAM-LV for EpCAM+ cells. (A) Cell entry is EpCAM dependent but independent of ephrin-B2. Representative flow
cytometry plots out of three independent experiments of CHO-K1, CHO-EpCAM, CHO-ephrin-B2 cells, and of a mixed culture composed of
CHO-EpCAM and CHO-ephrin-B2 (1:1 ratio) monitored 72 h after transduction with NiVmutEpCAM-LV, NiVwt-LV or VSV-LV (MOI of 1). EpCAM
expression was detected by an APC-coupled human EpCAM specific antibody. (B) To ascertain stability of transduction with the EpCAM-targeted
vector, CHO-EpCAM cells were cultivated for further 30 days after transduction with the indicated MOIs. The percentage of GFP-positive cells was
determined by flow cytometry at the indicated time points. One representative out of three independent experiments is shown.
doi:10.1371/journal.ppat.1005641.g003
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Surface expression levels of GcΔ34Her2mut4 and the corresponding MV-derived
HcΔ18mutHer2 did not differ and were slightly enhanced compared to GcΔ34His, which is most
likely due to a better recognition of the His-tag when displayed on top of the DARPin (Fig 8A).
Next, the ability of GcΔ34mutHer2mut4 to bind recombinant Her2/neu was investigated. For
Fig 4. Receptor usage of NiVmutEpCAM-LV. To determine the receptor usage of NiVwt-LV (A) in
comparison to NiVmutEpCAM-LV (B) a competition assay was performed by incubating the vector particles
(MOI 0.4) for 1 h at 4°C with increasing amounts of the entire extracellular domain of human ephrin-B2 (black
lines), ephrin-B3 (blue lines), human EpCAM (red lines) or murine EpCAM (grey lines). Following incubation,
cells were transduced and analyzed for GFP expression by flow cytometry 72 h post transduction. Data are
normalized to transduction efficiency measured without pre-incubation with recombinant protein (n = 3). (C)
CHO-EpCAM and CHO-ephrin-B2 cells (1x104) were pre-treated with increasing amounts of bafilomycin A1
for 30 minutes prior to transduction of cells with NiVmutEpCAM-LV and NiVwt-LV at an MOI of 0.4. VSV-LV
served as a control as cell entry of this vector is described to be pH-dependent. Relative transduction rates
compared to cells transduced in absence of bafilomycin A1 were determined by flow cytometry 72 h post
transduction (n = 3).
doi:10.1371/journal.ppat.1005641.g004
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this purpose, HEK-293T cells transfected with plasmids encoding GcΔ34Her2mut4,
HcΔ18mutHer2, or GcΔ34His were incubated with Her2/neu and subsequently stained for Her2/
neu binding. As expected, GcΔ34His and mock transfected cells showed no binding of Her2/
neu. In contrast, the NiV- and MV-based Her2/neu-specific constructs showed an identical
binding efficiency of recombinant Her2/neu (Fig 8B).
To quantitatively compare the amounts of GcΔ34Her2mut4 and HcΔ18mutHer2 in LV parti-
cles, we applied different amounts of particles from several independently generated batches of
vector stocks to Western blot analysis making use of the His-tag in both proteins for detection.
There were reproducibly higher amounts of G than of H protein present in each batch and
dilution analyzed (Fig 8C and 8D). At the highest dilution, H was detectable in only one sam-
ple. On the average of all dilutions and vector batches analyzed, there was 3.14 ± 0.66 (n = 8)
fold more GcΔ34Her2mut4 than HcΔ18mutHer2 incorporated. Since GcΔ34Her2mut4 was able to
bind Her2/neu and was incorporated into LV particles at even higher levels than
HcΔ18mutHer2, we tested next, if the vector particles had lost their gene transfer activity due to
an increased endocytosis and subsequent degradation by endo-lysosomal proteases. For this
purpose, endosomal acidification of SK-OV-3 cells (positive for Her2/neu and ephrin-B3) was
Fig 5. Expanding the system to additional target receptors. (A) Surface expression of NiV G proteins (blue line) targeted to four different receptors
was compared to that of the corresponding MV H protein counterparts (red line). All expression plasmids encoding the different constructs were
transfected into HEK-293T cells. Surface expression was analyzed after 48 hours using a His-tag-specific antibody (PE-labeled). Mock transfected cells
(filled curves) served as negative control. One representative out of three experiments is shown. For quantitative data see S3 Fig. (B) Western blot
analysis of NiVmutEpCAM-LV, NiVmutCD8-LV, NiVmutCD20-LV, and NiVmutHer2-LV. For generation of the vectors used for Western blot analysis, F protein
C-terminally tagged with the AU1 immunological tag was used to allow detection via the anti-AU1 antibody. Incorporation of the G variants was detected
via an anti-His antibody. 2.5x1010 particles per sample were used. Mock transfected cells (mock) as well as bald particles without glycoproteins (bald-
LV) served as controls. In addition, particles pseudotyped with full-length His-tagged G and AU1 tagged F (GHis-LV) as well as particles pseudotyped
with GcΔ34His/FcΔ22-AU1 (NiVwt-LV) were used. For quantitative data see S4 Fig. (C) Titers of receptor-targeted NiV-LVs and their MV-LV
counterparts. Unconcentrated stocks of EpCAM-targeted vectors were titrated on CHO-EpCAM cells, CD20-targeted vectors on Raji, CD8 targeted-
vectors on Molt4.8 and Her2/neu-targeted vectors on SK-OV-3 cells. (n = 4; mean ± standard deviations (SD) are shown; *, P<0.1; ***, P<0.001; ****,
P<0.0001 by unpaired t-test). (D) Fold change in titers (t.u./ml) determined by normalizing the titers of NiV glycoprotein based LVs to those of the
corresponding MV glycoprotein based LVs. (E) Concentration of vector stocks from (C) by centrifugation. (F) Number of transducing units per 108
physical particles of NiV and MV glycoprotein based LVs. Particle numbers were determined by single nanoparticle tracking analysis (NTA) (n = 4;
mean ± standard deviations (SD) are shown; *, P<0.1; ***, P<0.001; ns, not significant by unpaired t-test).
doi:10.1371/journal.ppat.1005641.g005
Fig 6. Neutralization of NiV glycoprotein pseudotyped LVs.CHO-EpCAM or CHO-ephrin-B2 cells were
transduced with NiVmutEpCAM-LV (blue), MVEpCAM-LV (red), NiVwt-LV (black), or VSV-LV (grey) at an MOI of
0.4 after incubation with serial dilutions of pooled human serum (IVIG) for 2 h at 37°C. After 72 h, GFP+ cells
were determined by flow cytometry. The number of GFP+ cells relative to the untreated control is shown
(n = 3).
doi:10.1371/journal.ppat.1005641.g006
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blocked by bafilomycin A1. As shown before, transduction by VSV-LV was inhibited whereas
transduction by NiVwt-LV was not influenced (Fig 8E). Interestingly, gene transfer by NiV-
mutHer2-LV was rather enhanced by bafilomycin A1 by a factor similar to that seen for
Fig 7. Selective transduction of CD8+ human PBMC. (A) Freshly isolated human PBMCwere activated for three days and then transduced
with NiVmutCD8-LV, NiVwt-LV or VSV-LV at an MOI of 2, respectively. Representative flow cytometry plots out of three independent
experiments are shown. GFP fluorescence was measured via flow cytometry at day 5, 10 and 17 after transduction. CD8+ cells were stained
with APC coupled anti-CD8 antibody. (B) Percentage of GFP positive cells within the CD8+ population was measured at day 5, 10 and 17
after transduction (n = 3).
doi:10.1371/journal.ppat.1005641.g007
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NiVmutEpCAM-LV (Figs 8E and 4C). Thus, the defect in transduction of the Her2/neu specific
NiV-LV was likely not caused by loss of particles to acidified endosomal compartments.
DARPin 9.29 had been used in NiVmutHer2-LV as this targeting domain was found to be
the best for the MV-glycoprotein-based system [30]. To test, if the targeting domain may make
a difference, DARPin 9.29 was exchanged against five different Her2/neu specific DARPins
(9.01, 9.16, 9.26, H14R, G3) [34,35] and one trastuzumab-derived scFv (4D5++) [36]. All
GcΔ34mut4 fusion proteins were expressed on the surface of HEK-293T producer cells, with a
tendency for the 9.29 DARPin to mediate higher and the scFv 4D5++ to mediate lower expres-
sion levels (Fig 8F). Particle incorporation levels for most of the new G variants were in the
same range as that for the 9.29 displaying GcΔ34mut4, with the only exception for the scFv
4D5++ (Fig 8G; S8 Fig). Notably, DARPins H14R and G3 as well as the scFv 4D5++ mediated
gene transfer activities comparable to or even higher than that of MVHer2-LV (Fig 8H).
Enhanced binding to Her2/neu could be excluded as being causative, since GcΔ34mut4 pro-
teins fused to these targeting ligands were similar or rather less efficient in binding Her2/neu
(S9 Fig). Remarkably, the two DARPins as well as the scFv bind to domain IV of Her2/neu, the
most membrane-proximal domain, whereas the four other DARPins, which resulted in low
functional titers, bind to domain I [34,35,37].
To further investigate a potential preference of the NiV glycoproteins for membrane-proxi-
mal binding sites, we targeted NiV-LV particles to two further receptors with large extracellular
parts, the human c-kit receptor (CD117) and the glutamate receptor 4 (GluA4). CD117 was
targeted by displaying its natural ligand stem cell factor (SCF), and GluA4 by a recently selected
DARPin, in each case via a (G4S)3 linker on GcΔ34mut4. CD117 is a tyrosine kinase receptor
composed of five Ig-like domains of which the first two domains supported by domain III form
the SCF binding site [38]. The crystallized extracellular part of CD117 forms a rigid structure
which projects the SCF binding site away from the cell membrane by about 120 Å [38,39].
GluA4 is a typical channel protein with an amino-terminal domain (ATD) reaching up to 120
Å away from the cell membrane. As alternative receptors, we moved domains I-III of CD117
by about 70 Å and the ATD of GluA4 by about 50 Å closer to the cell membrane by fusing
them to the CD4 transmembrane domain, respectively. All receptors were stably expressed in
Fig 8. Characterization of NiVmutHer2-LV. (A) Surface expression of GcΔ34mutHer2 and HcΔ18mutHer2 in comparison to GcΔ34His on HEK-293T cells
transiently transfected with plasmids encoding the different glycoproteins compared to mock transfected cells as determined by flow cytometry. Cells were
stained with PE coupled anti-His antibody. Mean fluorescence intensities of three independent measurements are shown (n = 3; mean ± standard
deviations (SD) are shown; ns, not significant by unpaired t-test). See S6 Fig for exemplary raw data. (B) Binding of recombinant Her2/neu to the
engineered glycoproteins. GcΔ34Her2mut4, HcΔ18mutHer2 and GcΔ34His were expressed in HEK-293T cells, incubated for 1 h at 4°C with 1 µg/ml
recombinant Fc-Her2/neu prior to staining against the Fc-tag using FITC coupled anti-Fc antibody. Mean fluorescence intensities of three experiments are
shown (n = 3; mean ± standard deviations (SD); ns, not significant by unpaired t-test). See S6 Fig for exemplary raw data. (C) Western blot analysis of NiV-
and MV-based Her2/neu targeted LVs. 2.5x1010 (1), 1.25x1010 (0.5), 6.25x109 (0.25) and 3.125x109 (0.125) particles were applied per sample, respectively.
The glycoproteins G and H were detected by anti-His antibody. The NiV F glycoprotein was detected via the AU1-tag specific antibody. One representative
out of threeWestern blots is shown. The central lane between the NiV and MV samples containing the molecular weight marker was removed. (D)
Incorporation levels of GcΔ34Her2mut4 and HcΔ18mutHer2. Three independently generated stocks of NiVmutHer2-LV and MVHer2-LV were subjected to
Western blot analysis applying four different particle numbers as shown in (C). Average chemiluminescence values for the glycoproteins G and H were then
normalized to those of p24 (n = 3 for all NiVmutHer2-LV dilutions and MVHer2-LV dilutions 1 and 0.5; n = 2 for dilutions 0.25 and n = 1 for dilution 0.125 of
MVHer2-LV; mean ± standard error of the mean (SEM) are shown). (E) Bafilomycin A1 sensitivity of NiVmutHer2-LV. NiVmutHer2-LV, NiVwt-LV and VSV-LV
were titrated on SK-OV-3 cells in presence or absence of 20 nM bafilomycin A1. Relative titers of vectors in presence of bafilomycin A1 to untreated control
are shown (n = 3). (F) Exchanging the DARPin 9.29 with alternative Her2/neu-specific targeting domains. Mean fluorescence intensities of surface
expression of GcΔ34Her2mut4 variants in which DARPin 9.29 was replaced by DARPins 9.01, 9.16, 9.26, H14R, G3 or the scFv 4D5++ after transient
transfection of HEK-293T cells with the corresponding expression plasmids compared to mock transfected cells as determined by flow cytometry. Cells
were stained with PE-coupled anti-His antibody (n = 4; mean ± standard deviations (SD) are shown). Examples of representative flow cytometry plots are
shown in S7 Fig. (G) Western blot analysis of the different NiV glycoprotein based vectors targeted to Her2/neu. The G variants were detected via an anti-
His antibody, and F by AU1-tag specific antibodies. 2.5x1010 particles per sample were applied. Mock transfected cells (mock) as well as bald particles
without glycoproteins (bald-LV) served as controls. In addition, particles pseudotyped with full-length His-tagged G and AU1 tagged F (GHis-LV) as well as
particles pseudotyped with GcΔ34His/FcΔ22-AU1 (NiVwt-LV) were used. For quantitative data see S8 Fig. (H) Titers of concentrated vector stocks of the
different Her2/neu specific NiV-LVs and of MVHer2-LV as determined on SK-OV-3 cells (n = 3; mean ± standard deviations (SD) are shown).
doi:10.1371/journal.ppat.1005641.g008
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human fibrosarcoma HT1080 cells. The GcΔ34mut4 variants as well as the receptors were readily
detected at the cell surface by flow cytometry with a tendency for the shortened receptors to
reach lower surface expression levels (Fig 9A and 9B; S10 Fig). For CD117 this was verified by
using recombinant SCF instead of the CD117-specific antibody to detect surface expression (Fig
9C; S10 Fig). The titers of NiVmutCD117-LV and of NiVmutGluA4-LV particles were in a similar
low range as that of NiVmutHer2-LV when added to cells expressing the unmodified receptors
(Fig 9D). Titers increased by at least 20-fold on cells expressing the shortened receptors (Fig 9D),
thus supporting the idea of more efficient cell entry via membrane proximal receptors.
Discussion
Here we describe successful engineering of the NiV glycoproteins for LV pseudotyping and
receptor targeting, which allowed us to rapidly generate a large series of glycoprotein variants
Fig 9. CD117- and GluA4-targeted NiV-LVs. (A) Surface expression of CD117 (blue line) and CD117short
(red line) on stably expressing HT1080 cells compared to the parental cell line (filled curve) as determined
by flow cytometry. Cells were stained with PE-coupled CD117 antibody. One representative out of four
experiments is shown. See S10 Fig for quantitative data. (B) Surface expression of GluA4 (blue line) and
GluA4short (red line) on stably expressing HT1080 cells compared to the parental cell line (filled curve) as
determined by flow cytometry. Cells were stained with PE-coupledmyc-tag antibody. One representative out of
three experiments is shown. See S10 Fig for quantitative data. (C) Binding of recombinant SCF to CD117 and
CD117short. Fc-SCFwas produced in HEK-293T cells by transient transfection. HT1080, HT1080-CD117 and
HT1080-CD117short were incubated for 1 h at 4°C with the same volumes of recombinant Fc-SCF prior to
staining against Fc-tag using FITC coupled anti-Fc antibody. One representative out of three experiments is
shown. See S10 Fig for quantitative data. (D) Titers of concentrated stocks of NiVmutCD117-LV and NiVmutGluA4-
LV. NiVmutCD117-LV was titrated on HT1080-CD117 and HT1080-CD117short cells (n = 4; mean ± standard
deviations (SD) are shown; **, P<0.01by unpaired t-test). NiVmutGluA4-LV was titrated on HT1080-GluA4 and
HT1080-GluA4short cells (n = 3; mean ± standard deviations (SD) are shown; ***, P<0.001 by unpaired t-test).
doi:10.1371/journal.ppat.1005641.g009
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attaching to a variety of cell surface proteins and assessing cell entry. For pseudotyping, distinct
truncations in G (GcΔ33 and GcΔ34) and F protein (FcΔ22) were found to be optimal. Our
data are thus in line with those of Witting et al (2013) for G protein, and with those of Palo-
mares et al. (2012) for F protein. For both, F and G, the enhanced titers correlated well to an
enhanced incorporation into LV particles, suggesting steric hindrance as likely explanation for
the need for cytoplasmic tail truncations.
In the second engineering step we eliminated use of the natural NiV receptors ephrin-B2
and ephrin-B3 by introducing point mutations into the GcΔ34EpCAM protein. For identifying
the most effective mutations, we relied on the G protein structure and previously identified
contact residues [22,23,25,26]. Yet, this turned out to be challenging, since the picomolar affin-
ity of G for ephrin-B2 is among the strongest viral envelope-receptor interactions known
[40,41]. Accordingly, we found that mutations E533A and W504A, the previously identified
key residues for receptor attachment [22,23], were not sufficient to destroy ephrin-B2 binding
completely, either individually or in combination (E533A/Q530A and E501A/W504A). How-
ever, combining both double mutations ultimately diminished binding to a level below detection.
Importantly, transduction via the targeted EpCAM receptor was unimpaired by these mutations.
Off-target transduction tested in CHO cells overexpressing ephrin-B2 was barely detectable and
at least 1000-fold reduced when compared to the transduction of CHO cells overexpressing
EpCAM. Since ephrin-B2 is widely expressed in the organism, including microvascular endothe-
lial cells [42], having achieved complete abrogation of LV particle attachment to ephrin-B2 is an
important step towards efficient in vivo gene delivery with receptor-targeted LVs.
NiV and MV enter cells by pH-independent membrane fusion at the cell membrane.
EpCAM is known to be rapidly internalized upon antibody binding [21,43]. It is therefore
likely that also binding of EpCAM-targeted vector particles induces internalization of EpCAM
together with the bound particle. Interestingly, bafilomycin A1 enhanced gene delivery by NiV-
mutEpCAM-LV but, as expected, substantially reduced that mediated by VSV-LV, which is
known to rely on pH-dependent entry [28]. Bafilomycin A1 is a selective inhibitor of the
V-ATPase preventing the influx of protons into endosomes [44,45]. Thus, in the presence of
bafilomycin A1 endocytosed NiVmutEpCAM-LV particles are less degraded by pH-dependent
endo-/lysosomal proteases and can therefore enter the cytoplasm via fusion of the LV envelope
with the endosomal membrane more efficiently [46]. Notably, a similar observation has been
made for Her2/neu targeted MV-LVs using chloroquine as inhibitor [47]. Although being
more unspecific, chloroquine also neutralizes the low pH in endosomes. It is well conceivable
that in both settings more particles can escape the endosomes by membrane fusion and then
contribute to the observed enhanced gene delivery rates.
An unexpected observation of our study was the behavior of the Her2/neu-targeted
NiV-LV. In contrast to NiV-LVs targeted to CD8, EpCAM, or CD20, it was substantially
reduced in mediating gene transfer lagging behind its MV-based counterpart by about 30-fold.
Changes in cell surface expression, particle incorporation as well as Her2/neu binding could be
excluded as being causative. Also blocking proteolytic degradation after potential endocytosis
did not restore gene transfer activity to similar levels as that of the MV-based vector particles.
Among a panel of six further Her2/neu binding domains, however, two DARPins and a scFv
were identified that mediated substantially higher titers now being in the same range or even
exceeding those of the corresponding MV-based LVs. Vector particles displaying these Her2/
neu binding domains being active in mediating transduction neither contained more G protein
nor were they more active in binding Her2/neu. Strikingly, their binding sites invariably local-
ize to the membrane proximal domain IV of Her2/neu, while those of the four binding
domains mediating low transduction rates localize to the membrane distal domain I (Fig 10A).
Her2/neu is known to exist mainly in the so called “open” conformation in which the
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extracellular domains are straightened up and thus oriented almost perpendicularly to the cell
membrane [48]. Thus, vector particles binding to the membrane distal domain I of Her2/neuwill
be about 80 Å further away from the cell membrane than those displaying a domain IV-specific tar-
geting domain. The SCF binding site on CD117 (about 120 Å) and the ATD of GluA4 are similarly
far away from the cell membrane [38,39]. Indeed, titers of the NiV-LV particles targeted to these
receptors were in a similar low range as that of NiVmutHer2-LV, but increased by at least 20-fold
when we moved domains I-III of CD117 and the ATD of GluA4 closer to the membrane (Fig 10A).
In contrast to CD117, GluA4 and Her2/neu, the natural NiV receptor ephrin-B2 is a trans-
membrane protein with a single, rather small extracellular domain that brings the bound virus
particle similarly close to the cell membrane as domain IV of Her2/neu. This holds true also for
EpCAM and CD20, which both mediated efficient entry of the targeted NiV-LV particles (Fig
10A). The extracellular part of CD8α is composed of a single immunoglobulin (Ig)-like domain
linked to a thin stalk sequence of 47 residues. Although the 3D structure of the stalk is not
available, it is assumed to be highly flexible, thus also allowing a close proximity of vector parti-
cles having attached to the Ig-like domain [49].
Fig 10. Position of the binding site on the targeted receptor determines cell entry. (A) Three-dimensional structures of the targeted receptors and the
positions of their binding sites relative to the cell membrane. Surface representation of the extracellular domains of ephrin-B2 (PDB ID: 2VSM), EpCAM (PDB
ID: 4MZV), CD20 (PDB ID: 3PP4), CD8 (PDB ID: 1CD8), Her2/neu (PDB ID: 1N8Z), CD117 (PDB ID: 2E9W), CD117short (adapted from PDB ID: 2E9W).
For GluA4 the crystal structure of the closely related GluA2 including the transmembrane domain is shown (PDB ID: 3KG2). For GluA4short, the amino
terminal domain (ATD) of GluA4 (PDB ID: 4GPA) is shown. Non-crystalized membrane-proximal amino acids (aa) of undefined structure are indicated with
blue dots, each dot representing about 20 residues (ephrinB2: 64 aa; CD20: 25 aa (the structure of the small 6 aa loop is not available either); CD8α: 47 aa;
Her2/neu: 23 aa; CD117: 17 aa; CD117short: 24 aa, GluA4short: 24 aa). When available, the structure of the complex between the target receptor and the
targeting domain (red) is shown: Her2/neuwith bound DARPin-9.29 (D-9.29, PDB ID: 4HRL) and DARPin-G3 (D-G3, PDB ID: 4HRN) (adapted from [37]).
The CD117 ligand, SCF, is shown bound to CD117 and CD117short. For the natural NiV receptor ephrin-B2 the complex with the bound NiV-Gmonomer is
shown. (B) Molecular model for the distance effect and its implication for NiV-mediated membrane fusion. In absence of receptor binding, F is in its prefusion
state with the fusion peptide (light blue) being covered within the globular head (left). Upon attachment of G to its cell surface receptor, conformational
changes are induced resulting in the projection of the fusion peptide followed by its insertion into the cell membrane (top right). If the attached binding site on
the receptor is too far away from the cell membrane, the fusion peptide cannot insert and cell entry will not proceed (bottom right). Model adapted from [2] and
[50].
doi:10.1371/journal.ppat.1005641.g010
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Taken together, we thus have experimental evidence from three different receptors that
changing the distance of the attachment site relative to the plasma membrane makes a huge
difference in particle entry. Thereby, it was irrelevant if we altered the distance by receptor
engineering (CD117, GluA4) or by displaying targeting domains that bind to more membrane-
proximal epitopes (Her2/neu). We can therefore conclude, with only some uncertainty for
CD8, that gene delivery mediated by NiV-LVs at high efficiency requires binding of cell surface
receptors close to the cell membrane within a maximal distance of about 50 Å. Receptor attach-
ment in distances clearly beyond this results in a substantially reduced gene delivery efficiency,
most likely due to inefficient or absent membrane fusion.
How can we imagine that the distance between attachment site and cellular membrane
makes such a huge difference for pH-independent membrane fusion mediated by the NiV gly-
coproteins? It is important to realize that NiV-LV particles are completely covered with glyco-
proteins (Fig 2F). Thus upon cell attachment, a rigid scaffold will be formed between viral and
cellular membranes by numerous glycoprotein-receptor contacts. These trigger conformational
changes in G and F, which then projects the fusion peptide on top of a long coiled-coil struc-
ture, the heptad repeat A (HRA), towards the cell membrane [2]. In its fully extended, so called
prehairpin intermediate state, F can cover a maximal distance of 210 Å between the viral and
the cellular membrane [50]. Although the structure of the prehairpin intermediate has so far
only been modeled for parainfluenza virus 5 (PIV5), we can assume a very similar distance for
the NiV F protein, since structure and size of HRA and HRB (adjacent to the transmembrane
domain) are well conserved among paramyxoviruses [51,52] and the recently crystallized pre-
fusion form of NiV F exhibits an overall similar size as that of PIV5 [53]. With G protein being
slightly bigger in size than F, and receptor attachment sites being located on top of the globular
heads of G [25,26], we estimate the natural receptor binding site being about 120 Å away from
the viral membrane. The conformational change in F can then cover an additional distance of
up to 90 Å. Any distance beyond that would not allow insertion of the fusion peptide into the
cell membrane. The distances we determined here for the G-receptor pairs which were ineffi-
cient in mediating vector particle entry were indeed above 90 Å. The most likely explanation
for our observations thus is an incompatible architecture of the fusion protein with rigid recep-
tors that expose binding sites for NiV more than 90 Å away from the cell membrane (Fig 10B).
While most of the paramyxoviruses use sialic acid as receptor and can thus choose between
many attachment sites exposed at various distances from the cell membrane, Henipa- and mor-
billiviruses using protein receptors must have adapted to receptors bringing them so close to
the cell membrane that the distance between both viral and cellular membrane can be covered
by their F protein.
Supporting this model, a study analyzing a panel of chimeric CD46-CD4 proteins to func-
tion as MV receptors demonstrated that putting the MV binding domains of CD46 on top of
the complete CD4 molecule (four extracellular Ig domains) strongly reduced membrane fusion
[54]. While this fits nicely to our observations for the NiV glycoproteins, targeting MV-pseu-
dotyped LVs to the membrane distal domain of Her2/neu did not affect gene delivery (Fig 5C)
[30]. A prominent difference between MV-LVs on one hand and NiV-LVs as well as MV on
the other is the level of incorporated glycoproteins. NiV-LVs are completely covered with gly-
coproteins (Fig 2F) as it is the case for MV particles [55]. MV-LV particles, in contrast, con-
tained on average more than three-fold less H than NiV-LVs G protein. Thus, LV particles
pseudotyped with MV glycoproteins bind to cells via very few or even single receptor contacts,
which leaves them more flexibility to take a position within an optimal distance to the cell sur-
face for membrane fusion. This may well help MV-LVs to better compensate when being
bound to a membrane distal domain of a receptor. For NiV-LVs, in contrast, this may not be as
easily possible since they form many receptor contacts resulting in a much more rigid complex
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between virus particle and target cell. Moreover, the henipavirus G proteins are unique among
all paramyxoviruses, including MV, in forming covalently linked tetramers (dimers-of-dimers)
[56]. This could further contribute to a more rigid receptor-attachment protein complex for
NiV than for MV, which in turn results in higher sensitivity towards membrane-distal receptor
attachment.
In summary, the data presented in this manuscript imply that for the engineering of cell-
type-specific LVs, binding domains should be used bringing the particles within a close
distance to the cell membrane. By applying this to NiV-LVs, important progress in the engi-
neering of cell-type specific LVs has been made. Titers of these vectors are substantially
enhanced compared to vectors pseudotyped with engineered MV glycoproteins. The reasons
for this could be allocated to an increased number of particles released from packaging cells
which is most likely due to the intrinsic budding capability of the NiV glycoproteins [57]. Sec-
ond, the particles are more active in delivering the packaged gene which is likely the conse-
quence of the substantially higher glycoprotein density of NiV-LV particles compared to
MV-LVs. Since NiV-LVs can be produced at titers exceeding 106 t.u./ml, they will better qualify
for scale up and GMP production—an important requirement for applying receptor-targeted
LVs in clinical settings.
Materials and Methods
Generation of constructs
The plasmid pHL3-Ac1 coding for truncated and mutated MV HcΔ18mut protein and for a
(G4S)3 linker (L3) between H and the His-tagged DARPin Ac1 was generated by inserting the
PCR-amplified coding sequence of the EpCAM specific DARPin Ac1 [21] from pQE30s-
s_Ac1_corr into the backbone of plasmid pHL3-HRS3opt2#2 [58] via SfiI/NotI. All plasmids
encoding Nipah virus G protein variants were derived from pCAGGS-NiV-G [59]. The coding
sequence for the Ac1 targeting domain was fused to the C-terminus of the G protein reading
frame by PCR amplification of each fragment and simultaneously introducing a common AgeI
restriction site, which was used for ligation resulting in plasmid pCAGGS-NiV-GEpCAM. All
other targeting domains (DARPins or scFv) were exchanged via AgeI/NotI, resulting in the cor-
responding expression plasmids encoding GcΔ34 fused to the targeting domain. Truncations
of the G protein cytoplasmic tail were introduced by PCR of the G protein reading frame and
insertion of the PCR fragments into pCAGGS-NiV-GEpCAM resulting in plasmids pCAGGS-
NiV-GcΔ33EpCAM and pCAGGS-NiV-GcΔ34EpCAM.
The His-tagged GHis and GcΔ34His proteins were generated by PCR amplification from
pCAGGS-NiV-G. The fragments were cloned via PacI/NotI restriction into the plasmid back-
bone of pCAGGS-NiV-GEpCAM resulting in pCAGGS-NiV-GHis and pCAGGS-NiV-GcΔ34His,
respectively. Mutations interfering with natural receptor recognition were introduced into the
NiV-GcΔ34EpCAM protein coding sequence by site-directed mutagenesis. Each mutation was
generated by amplification of two fragments carrying the designated mutation with homolo-
gous regions at the mutation site. These fragments were fused and amplified by a flanking
primer pair. Resulting fragments were cloned into pCAGGS-NiV-GcΔ34EpCAM via RsrII/AgeI,
generating the plasmids pCAGGS-NiV-GcΔ34EpCAMmut.
For the generation of the NiV-F variants, the coding sequences for FcΔ22 [60] and FcΔ25
were amplified from pCAGGS-NiV-F [59] and cloned via PacI/SacI restriction into the plas-
mid backbone of pCAGGS-NiV-G resulting in the plasmids pCAGGS-NiV-FcΔ22 and
pCAGGS-NiV-FcΔ25. AU1 tagged NiV-F variants used for Western blot analysis of vector par-
ticles were generated by amplifying the NiV-F variants from pCAGGS-NiV-F and simulta-
neously adding the AU1 tag C-terminally. The resulting PCR fragments were cloned via PacI/
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SacI into the backbone of pCAGGS-NiV-G, resulting in the plasmids pCAGGS-NiV-F-AU1,
pCAGGS-NiV-FcΔ22-AU1, and pCAGGS-NiV-FcΔ25-AU1.
For sequences of primers used for the PCR reactions see S1 Table.
Cell culture
HEK-293T (ATCC CRL-11268), U87-MG (ATCC HTB-14) and CHO-K1 (ATCC CCL-61)
cells were grown in Dulbecco’s modified Eagle’s medium (DMEM) (Sigma-Aldrich, Munich,
Germany) supplemented with 10% fetal calf serum (FCS) (Biochrom, Berlin, Germany) and 2
mM L-glutamine (Sigma-Aldrich, Munich, Germany). SK-OV-3 (ATCC HTB-77) cells were
grown in McCoy’s A5 medium (Sigma-Aldrich, Munich, Germany) supplemented with 10%
FCS and 1% L-glutamine. Raji (ATCC CCL-86) as well as Molt4.8 cells were grown in RPMI
1640 (Biowest, Nuaillé, France) supplemented with 10% FCS and 2 mM L-glutamine.
The cell lines CHO-EpCAM [61] and CHO-ephrin-B2 were derived from CHO-K1 cells
(ATCC CCL-61) and cultivated in the same medium in presence of 10 μg/ml puromycin
(Thermo Fisher Scientific, Waltham, USA). For generation of CHO-ephrin-B2 cells, the gene
encoding human ephrin-B2 was amplified from pCAGGS-EB2 [62] and cloned into a lentiviral
transfer vector resulting in the bicistronic plasmid pS-ephrin-B2-IRES-puro-W. CHO-K1 cells
were transduced with LV particles having packaged the ephrinB2-IRES-puro sequence and
were selected using 10 μg/ml puromycin for 2 weeks.
HT1080-CD117 and HT1080-GluA4 cells were derived from HT1080 cells (ATCC CCL-121).
For this, the coding sequence for human CD117 was amplified via PCR from pCMV6-XL4-cKIT
(OriGene Technologies, Rockville, USA) and that of GluA4 from pk0002-Imyc [63] (kindly pro-
vided by Kari Keinänen), thereby adding an N-terminal myc tag. PCR fragments were then
cloned into the backbone of pS-ephrin-B2-IRES-puro-W (BamHI/SpeI) resulting in the bicistro-
nic plasmids pS-CD117-IRES-puro-W and pS-GluA4-IRES-puro-W, respectively. For the short-
ened receptor versions, the coding sequence for domains I-III of human CD117, and of the
amino terminal domain (ATD) of murine GluA4 were fused to that of the CD4 transmembrane
domain, respectively, and cloned into the backbone of pS-ephrin-B2-IRES-puro-W (BamHI/
SpeI) resulting in pS-CD117short-IRES-puro-W and pS-GluA4short-IRES-puro-W. HT1080
cells were transduced with LVs having packaged the receptor encoding constructs and selected
using 10 µg/ml puromycin for 2 weeks.
Primary PBMC were isolated from human buffy coats purchased from the German blood
donation center (DRK-Blutspendedienst Hessen, Frankfurt). PBMC were activated for 72 h in
RPMI 1640 supplemented with 10% FCS, 2 mM L-glutamine, 0.5% streptomycin/penicillin, 25
mMHEPES (Sigma-Aldrich, Munich, Germany), 100 U/ml interleukin-2 (R&D Systems, Min-
neapolis, USA), 1 μg/ml CD3 antibody (clone: OKT3, eBioscience, San Diego, USA) and 1 μg/
ml CD28 antibody (clone: CD28.2, eBioscience, San Diego, USA). Following transduction, cells
were cultivated in the same medium without OKT3 antibody and CD28 antibody.
LV production and transduction
Vector particles were generated by transient transfection of HEK-293T cells using polyethyle-
nimine (PEI). Twenty-four hours before transfection, 2.5x107 cells were seeded into a T175
flask. On the day of transfection, the cell culture medium was replaced by 10 ml DMEM with
15% FCS and 3 mM L-glutamine. The DNA mix was prepared by mixing 35 μg of total DNA
with 2.3 ml of DMEM without additives. For initial experiments (Fig 1B and 1D) 1.35 μg of
plasmid DNA encoding NiV-G wildtype or truncation mutants was mixed with 4.04 μg plas-
mid DNA encoding the NiV-F variants, 14.5 μg of the packaging plasmid pCMVΔR8.9 [64]
and 15.2 μg transfer vector pSEW encoding green fluorescent protein (GFP) as reporter [65].
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Following optimization of G to F ratios, 0.9 μg of plasmid encoding G protein variants were
mixed with 4.49 μg plasmid coding for F variants. The amounts of packaging plasmid and
transfer vector remained unchanged. LVs pseudotyped with the VSV glycoprotein G were gen-
erated by co-transfecting cells with 6.13 μg pMD2.G (kindly provided by Didier Trono, Lau-
sanne, Switzerland), 11.38 μg pCMVΔR8.9 and 17.5 μg pSEW. The transfection reagent mix
was prepared by adding 140 μl of 18 mM PEI solution in H2O to 2.2 ml DMEM without addi-
tives. This solution was combined with the DNA mix, vortexed, incubated for 20 minutes at
room temperature and added to the HEK-293T cells, resulting in DMEM with 10% FCS, 2 mM
L-glutamine in total. 24 h later, the medium was replaced by DMEM with 10% FCS, 2 mM L-
glutamine. At day two post transfection, cell supernatants containing the vector particles were
passed through a 0.45 μm pore size filter. If needed, vector particles were purified by centrifu-
gation at 4500 rpm for 24 h over a 20% sucrose cushion. The pellet was resuspended in phos-
phate-buffered saline (PBS).
For transduction, 8x103 of CHO-EpCAM and SK-OV-3 cells or 2x104 Molt4.8 and Raji
cells were seeded into 96-well-plate and transduced on the next day. When needed, cells were
pre-incubated for 30 min at 37°C with medium containing different concentrations of bafilo-
mycin A1 (Santa Cruz Biotechnology, Dallas, USA) before LVs were added. For titration, cells
were transduced with at least four serial dilutions of vector particles. After 72 h, the percentage
of GFP-positive cells was determined by flow cytometry and the transducing units per milliliter
(t.u./ml) were calculated by selecting the dilutions showing linear correlation between dilution
factor and number of GFP-positive cells. For transduction of primary PBMC, cells and vector
were spinfected by centrifugation at 850xg at 32°C for 90 minutes. Percentages of GFP-positive
cells were determined by flow cytometry at the indicated days post transduction.
Electron microscopy
For electron microscopy, concentrated NiVmutEpCAM-LV particles were adsorbed to glow dis-
charged formovar coated 200-mesh nickel grids for 5 min, washed three times with H2O and
contrasted with 2% aqueous uranyl acetate (Merck, Darmstadt, Germany) for 10 s. Samples
were analyzed with the EM109 transmission electron microscope (Zeiss, Jena, Germany).
Flow cytometry
Flow cytometry analysis was performed on the MACSQuant Analyzer 10 (Miltenyi Biotec, Ber-
gisch Gladbach, Germany). For surface expression experiments of Nipah virus G constructs,
HEK-293T cells were transfected with the corresponding expression plasmid. After 48 h,
adherent cells were detached with PBS-EDTA solution and subsequently washed in 800 µl
FACS washing buffer (PBS, 2% FCS, 0.1% NaN3), and incubated with a phycoerythrin (PE)-
conjugated mouse anti-His antibody (clone GG11-8F3.5.1, Miltenyi Biotec, Bergisch Gladbach,
Germany, dilution 1:100) in FACS washing buffer. Human EpCAM was detected by an Allo-
phycocyanin (APC) labeled mouse anti-EpCAM antibody (clone HEA-125, Miltenyi Biotec,
Bergisch Gladbach, Germany, dilution 1:100). CD117 and CD117short expression was detected
by staining with PE-coupled CD117 antibody (clone: 104D2; 1:100; BioLegend, San Diego,
USA). Expression of myc-tagged GluA4 and GluA4short was detected by staining with PE-
coupled anti-myc antibody (clone 9B11; 1:100; Cell Signaling Technology, Danvers, USA). Pri-
mary PBMC were transferred into FACS washing buffer, washed twice and CD8 expression
was detected by a human APC-conjugated anti-CD8 antibody (clone RPA-T8, 1:100, BD Bio-
sciences, San Jose, USA). After two additional washing steps, cells were resuspended in 100 µl
PBS containing 1% formaldehyde. Data were analyzed using FCS Express version 4.0 (De
Novo Software, Glendale, USA).
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Binding assay
1.4x106 HEK-293T cells were seeded into one well of a 6-well plate and transfected on the next day
with 1.92 µg plasmid DNA coding for the different NiV-G constructs. 48 h later, cells were detached
and 1x105 cells were washed with FACS washing buffer, incubated with 1 µg of the Fc-tagged extra-
cellular domain of human ephrin-B2, ephrin-B3 or Her2/neu (R&D Systems, Minneapolis, USA)
for 1 h at 4°C, washed again and subsequently stained with a FITC-tagged anti-human Fc antibody
(1:100, SouthernBiotech, Birmingham, USA). Samples were analyzed by flow cytometry.
Competition assay
NiVmutEpCAM-LV, MVEpCAM-LV, VSV-LV and NiVwt-LV were pre-incubated for 1 h at 4°C
with different amounts of soluble extracellular domains of human or murine EpCAM (Sino
Biological, Beijing, China) or human ephrin-B2 and B3 (R&D Systems., Minneapolis, USA),
respectively. Then, CHO-EpCAM or CHO-ephrin-B2 cells were transduced with pre-incu-
bated LVs before GFP expression was analyzed after 72 h by flow cytometry.
Neutralization assay
CHO-EpCAM and CHO-ephrin-B2 cells were transduced at a multiplicity of infection (MOI)
of 0.4 with NiVmutEpCAM-LV, MVEpCAM-LV, VSV-LV and NiVwt-LV that have been pre-
incubated with serial dilutions of intravenous immunoglobulins (IVIG, Intratect, Biotest,
Dreieich, Germany) for 2 h at 37°C. After 72 h, the percentage of GFP-positive cells was deter-
mined by flow cytometry.
Nanoparticle tracking analysis of lentiviral particles
Particle size and concentration of LVs was determined using the NanoSight NS500 instrument
(Malvern Instruments, Worcestershire, UK). Concentrated vector stocks were diluted in
degassed PBS to contain between 1x107 and 1x109 particles/ml and measured five times for 90
s at 25°C. NTA2.3 software (Malvern Instruments, Worcestershire, UK) was used for particle
identification, size analysis and determination of particle concentration.
Western blot analysis
Concentrated vector particles were denatured by incubation with 2x urea sample buffer (5%
sodium dodecyl sulfate, 8 mM urea, 200 mM Tris-HCl, 0.1 mM EDTA, 0.03% bromphenol
blue, 2.5% dithiothreitol, pH 8.0) for 10 minutes at 95°C, separated by gel electrophoresis on
10% sodium dodecyl sulfate-polyacrylamid electrophoresis gels, and blotted onto nitrocellulose
membranes (GE Healthcare, Freiburg, Germany). Blots were incubated with mouse anti-His
(clone 27E8, 1:1,000; Cell Signaling Technology, Danvers, USA) for detection of His-tagged
NiV and MV glycoproteins, mouse anti-p24 (clone 38/8.7.47, 1:1,000; Gentaur, Aachen, Ger-
many) for detection of the LV core protein p24 or goat anti-AU1 antibody for detection of
AU1-tagged NiV F protein (1:1,000; Thermo Fisher Scientific, Waltham, USA). Subsequently,
horseradish peroxidase conjugated secondary antibodies (1:2,000; DakoCytomation, Hamburg,
Germany) were used and signals were detected using the ECL Plus Western Blotting Detection
System (Thermo Fisher Scientific, Waltham, USA). Released photon units were then quantified
using the IVIS Spectrum (PerkinElmer, Waltham, USA). To determine the photon intensities
of bands corresponding to the glycoproteins and to p24, areas corresponding to the respective
bands were manually defined using the Living Image 4.3.1 software (PerkinElmer, Waltham,
USA). Background activities were identified by the negative control samples and subtracted
from the glycoprotein and p24 signals.
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